Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.53 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26779718 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MTNR1AMTNR1BHTTTSHR | |
| SCHEMBL17335683 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MTNR1AMTNR1BHTTTSHR | |
| SCHEMBL20990440 | 0.91 | ALDH1A1 (0.74) | ALDH1A1HTTTSHRHPGDMEN1 | |
| SCHEMBL659023 | 0.91 | ALDH1A1 (0.74) | ALDH1A1HTTTSHRHPGDMEN1 | |
| Hydrochloric Acid SCHEMBL7797522 | 0.90 | ALDH1A1 (0.72) | ALDH1A1HTTTSHRHPGDMEN1 | |
| SCHEMBL2464640 | 0.88 | ALDH1A1 (0.64) | ALDH1A1MTNR1AMTNR1BHTTTSHR | |
| SCHEMBL19115277 | 0.88 | ALDH1A1 (0.64) | ALDH1A1MTNR1AMTNR1BHTTTSHR | |
| SCHEMBL21766236 | 0.87 | ALDH1A1 (0.64) | ALDH1A1HTTTSHRPDPK1HPGD | |
| SCHEMBL5969797 | 0.87 | ALDH1A1 (0.64) | ALDH1A1HTTTSHRPDPK1HPGD | |
| SCHEMBL7154380 | 0.87 | ALDH1A1 (0.64) | ALDH1A1HTTTSHRPDPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | disclosed |
| US-5721234-A | TREATING CONVULSIONS, ANXIETY, CEREBRAL HYPOXIA/ISCHEMIA, PARKINSON*S DISEASE | WARNER-LAMBERT COMPANY (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996017832-A1 | NOVEL GLUTAMATE RECEPTOR ANTAGONISTS: FUSED CYCLOALKYLQUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | ALDH1A1 4135/4885MTNR1A 238/4885MTNR1B 261/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ALDH1A1 1598/4885MTNR1A 823/4885MTNR1B 815/4885 |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | ALDH1A1 385/4885MTNR1A 348/4885MTNR1B 225/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ALDH1A1 1601/4885MTNR1A 773/4885MTNR1B 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.